ArcaScience utilizes artificial intelligence to analyze and enrich extensive biomedical datasets, creating a patient-centric database with over 100 billion data points. This technology enables healthcare professionals to identify promising drug candidates and monitor safety issues, enhancing the efficiency and safety of drug development processes.
Funding
Funding not disclosed
AMPAFounders
Product
Problem
The process of bringing new drugs to market is often slowed by inefficient data analysis and difficulties in identifying potential safety issues early in development. Traditional methods struggle to effectively integrate and analyze the vast amounts of biomedical data required for comprehensive drug evaluation.
Solution
ArcaScience leverages artificial intelligence to analyze and enrich extensive biomedical datasets, creating a patient-centric database containing over 100 billion data points. This platform enables healthcare professionals to identify promising drug candidates and proactively monitor safety issues, thereby enhancing the efficiency and safety of drug development. ArcaScience offers AI-driven insights through tailored studies and reports, including benefit-risk prediction, safety monitoring, endpoint discovery, and KOL identification. These solutions streamline data analysis, allowing for more informed decision-making and de-risking clinical trials.
Target Audience
ArcaScience primarily serves biopharmaceutical companies, clinical trial leaders, and drug safety specialists seeking to improve drug development processes and patient safety through advanced data analysis.
Features
- AI-assisted benefit-risk prediction to differentiate promising drugs before clinical trials
- Safety Monitoring Reports for proactive detection of safety issues
- AI-assisted endpoint discovery to identify optimal clinical outcome assessments (COAs)
- AI-assisted KOL identification for targeted clinical trial recruitment
- A.S. Therapeutic Horizon: A search engine for simplified literature review
- A.S. Trial Scanner: Integrates data into eCRFs for real-world studies
- Patient profiles enriched with 100 billion data points